Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Population-based Integrative Analysis of Relapsed-Refractory Mature B-cell Non-Hodgkin Lymphoma in Children and Adolescents

ABSTRACT: Relapsed-Refractory Mature B-cell Non-Hodgkin Lymphoma in Children and Adolescents

PROVIDER: PRJEB76315 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Comprehensive Analysis of Relapsed-Refractory Mature B-cell Non-Hodgkin Lymphoma in Children and Adolescents

Project description:Outcome of paediatric B-cell Non-Hodgkin Lymphoma (B-NHL) has significantly improved in the last decades due to risk adapted strategies and the addition of immunotherapy, (survival >90%). However, limited progress has been achieved in relapsed patients, mostly Burkitt lymphoma (<30%). Validation of prognostic biomarkers to identify candidates to novel therapies is imperative. This retrospective study reports on clinical and therapeutic data of 46 children and adolescents with relapsed B-NHL, including integrative molecular data of 16 (35%) cases. TP53 alterations were identified in 10 (60%) patients which were associated with worse outcome. Our data support the focus on TP53 as a potential biomarker.

2025-02-27 | GSE269220 | GEO

Comprehensive Analysis of Relapsed-Refractory Mature B-cell Non-Hodgkin Lymphoma in Children and Adolescents

Project description:Comprehensive Analysis of Relapsed-Refractory Mature B-cell Non-Hodgkin Lymphoma in Children and Adolescents

| PRJNA1120752 | ENA

Expression Profile of Relapsed/Refractory Aggressive B-cell Non Hodgkin Lymphoma Tumors

Project description:Expression Profile of Relapsed/Refractory Aggressive B-cell Non Hodgkin Lymphoma Tumors

| PRJNA720938 | ENA

DNA methylation of Relapsed/Refractory AML

Project description:DNA methylation of Relapsed/Refractory AML

| PRJNA934390 | ENA

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Project description:Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin lymphoma

| 2099626 | ecrin-mdr-crc

DNA methylation of Relapsed/Refractory AML

Project description:Genome wide DNA methylation profiling of blood and bone marrow of Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia. The Illumina Infinium EPIC Human DNA methylation Beadchip was used to obtain DNA methylation profiles across over 860,000 CpGs.

2023-12-31 | GSE225239 | GEO

ViPOR in Relapsed/Refractory B-Cell Lymphoma

Project description:ViPOR in Relapsed/Refractory B-Cell Lymphoma

| PRJNA1090979 | ENA

Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Project description:RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving vorinostat together with lenalidomide may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when given together with lenalidomide in treating patients with relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma.

| 2088557 | ecrin-mdr-crc

Genomic profiling of relapsed and refractory childhood cancers

Project description:Genomic profiling of relapsed and refractory childhood cancers

| PRJNA661355 | ENA

Genomic profiling of relapsed and refractory childhood cancers

Project description:Genomic profiling of relapsed and refractory childhood cancers

| PRJNA661354 | ENA